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ABSTRACT 
Background: The Recover Study is an ongoing, prospective study designed 
to assess toxicity associated with the use of nucleoside analogue reverse tran- 
scriptase inhibitors (NRTIs) (stavudine, zidovudine, lamivudine, didanosine, 
abacavir) in HIV-l-infected patients receiving highly active antiretroviral thera- 
py (HAART) in routine clinical practice. This project is being conducted at 120 
HIV units at teaching hospitals across Spain. 
Objective: The aim of this study was to identify the most common treatment- 
limiting moderate to severe clinical and laboratory adverse ffects (AEs), and the 
individual NRTIs involved in the development of these effects, in HIV-l-infected 
patients receiving HAART who discontinued use of an NRTI in the Recover Study. 
Methods: Patients eligible for participation in the Recover Study are aged 
->18 years; have virologically documented HIV-1 infection; have sustained viral 
suppression (viral load <200 cells/mL or stable, heavily experienced [ie, have 
received ->3 antiretroviral regimens] patients with viral load <5000 cells/mL) for 
_>6 months; are receiving HAART; are undergoing active follow-up; and have devel- 
oped ->1 NRTI-associated AE that, in the opinion of a study investigator and under 
the conditions of routine clinical practice, justified discontinuation of treatment 
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with the offending drug (principal AE/offending NRTI). The present study included 
patients recruited for the Recover Study between September 2002 and May 2003. 
Results: A total of 1391 patients were enrolled (966 men, 425 women; mean 
age, 42 years [range, 18-67 years]). Five hundred six patients (36.4%) had been 
diagnosed with AIDS. The mean duration of treatment with the offending NRTI 
was 74 months (range, 6-156 months). Seven hundred nine patients (51.0%) 
were receiving fourth-line (or more) therapy. Eight hundred twenty-one patients 
(59.0%) were receiving nonnucleoside analogues, and 552 patients (39.7%), pro- 
tease inhibitors, as components of their HAART regimens. The NRTIs with the 
highest discontinuation rates were stavudine (914 patients [65.7%]) and zido- 
vudine (177 [12.7%]). The most frequent NRTl-related AEs were lipoatrophy 
(550 patients [39.5%]) and peripheral neuropathy (170 [12.2%]). Lipoatrophy 
was most commonly associated with stavudine (480/550 cases [87.3%]); periph- 
eral neuropathy, with stavudine and didanosine (107/170 [62.9%] and 48/170 
[28.2%] cases, respectively); and anemia, with zidovudine (70/77 cases [90.9%]). 
Conclusions: The results of this study in patients with HIV-1 recruited in the 
Recover Study and undergoing HAART suggest hat long-term treatment with 
NRTIs is associated with AEs (lipoatrophy, peripheral neuropathy, and lipo- 
dystrophy), with morphologic disorders (lipoatrophy, lipodystrophy) being the 
most common AEs leading to discontinuation. Minimizing these AEs by switch- 
ing to an NRTI not associated with these AEs (eg, tenofovir) would contribute 
to adherence and hence efficacy of long-term HAART. (Curr Ther Res Clin Exp. 
2005;66:117-129) Copyright © 2005 Excerpta Medica, Inc. 
Key words: nucleoside analogue reverse transcriptase inhibitor toxicity, 
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INTRODUCTION 
Before the advent of highly active antiretroviral therapy (HAART) for the manage- 
ment of HIV-1 infection in the early 1990s, nucleoside analogue reverse transcrip- 
tase inhibitors (NRTIs) (stavudine, zidovudine, lamivudine, didanosine, abacavir) 
were the only drugs available for HIV-1. However, this drug class was associat- 
ed with a high rate of serious adverse ffects (AEs), which led to treatment limi- 
tations. With the efficacy of HAART, however, the spectrum of toxicity seems 
to have changed, and the awareness of AEs associated with long-term use of 
HAART regimens containing NRTIs has increased. 1 
In most cases, the HAART regimen includes 1 protease inhibitor (PI) or non- 
nucleoside reverse transcriptase inhibitor (NNRTI), combined with 2 NRTIs. 
The use of this treatment strategy has led to reductions in HIV-l-related mor- 
bidity and mortality. Mortality declined from 29.4 per 100 patient-years in 1995 
to 8.8 per 100 patient-years in 1997. 2 In many patients, these reductions are sus- 
tained in the long term. 2 However, morphologic disorders--changes in body 
composition and/or metabolism (eg, lipoatrophy, l ipodystrophy)--have b en 
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increasingly recognized in patients receiving HAART. 3 In particular, lipoatrophy, 
or subcutaneous fat wasting, in HIV-l-infected adults is disfiguring and poten- 
tially stigmatizing and has been associated with decreased adherence to and 
hence efficacy of HAART. 4-6 Although progressive, selective wasting of subcuta- 
neous fat in the face and limbs of HIV-l-infected patients receiving HAART has 
been attributed to long-term use of Pls, 7,8 fat wasting has also been observed in 
PI-naive patients, suggesting an independent effect of NRTI therapy. 9,1° 
Long-term treatment with NRTI-containing HAART regimens has been associ- 
ated with AEs including hyperlactatemia, l ctic acidosis, hepatic steatosis and 
other hepatotoxicities, pancreatitis, lipoatrophy/lipodystrophy, eripheral neu- 
ropathy, and hematologic toxicity. 1Of these, all but hematologic toxicity appear 
to have a common etiology involving the inhibition of polymerase-gamma 
action, which replicates mitochondrial DNA, leading to mitochondrial toxicities, 
which, in turn, lead to morphologic disorders. 11-13 Some of these AEs are seri- 
ous enough to warrant reatment discontinuation r regimen changes. 14 In ad- 
dition, it is sometimes difficult to determine the contributions of individual 
agents to the development of these AEs. 
The Recover Study is an ongoing, prospective study designed to assess tox- 
icity associated with NRTI therapy in HIV-l-infected patients receiving HAART 
in routine clinical practice. The study is being performed in 120 HIV units at 
teaching hospitals across Spain. The objective of the present study was to iden- 
tify the most common treatment-limiting moderate to severe clinical and labo- 
ratory AEs, and the individual NRTIs involved in the development of these 
effects, in HIV-l-infected patients receiving HAART who discontinued use of an 
NRTI in the Recover Study. 
PATIENTS AND METHODS 
According to the design of the Recover Study, patients are eligible for inclusion if 
they are aged ->18 years; have virologically documented HIV-1 infection; have sus- 
tained viral suppression (viral load <200 cells/mL or stable, heavily experienced [ie, 
have received _>3 antiretroviral regimens] patients with viral load <5000 cells/mL) 
for ->6 months; are receiving HAART; are undergoing active follow-up; and have 
developed ->1 NRTI-associated AE that, in the opinion of a study investigator and 
under the conditions of routine clinical practice, justified discontinuation f treat- 
ment with the drug. For the purposes of the present study, the AE leading to dis- 
continuation is referred to as the principal AE, and the NRTI associated with the 
principal AE and therefore discontinued is referred to as the offending NRTI. The 
fact that treatment with one particular NRTI was discontinued does not necessar- 
ily mean that the principal AE was caused by that NRTI--only that the principal AE 
has been shown to be associated with the NRTI. After the development of an AE, 
patients are followed up every 12 weeks until the AE resolves or up to 48 weeks. 
In the present prospective, observational study, patients recruited into the 
Recover Study cohort from September 2002 to May 2003 were included. At the 
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time the Recover Study was initiated, Spanish requisition did not require pro- 
tocol approval of an ethics committee. Patients included in the study were 
informed of the protocol and provided verbal informed consent o have their 
data included in the Recover database. The confidentiality of the information in 
the database is safeguarded based on Spanish law. This database is registered 
in the Agencia Espanola de Protecci6n de Datos, an agency that warrants the 
confidentiality of all data. 
Identif ication of Toxicities 
In the Recover Study, clinical and laboratory NRTI-associated abnormalities 
are recorded. Clinical abnormalities are identified using qualitative physical 
examination. Laboratory analysis includes serum chemistry and hematology. 
Blood samples are also obtained for HIV-1 RNA measurement and T-cell subset 
analyses. 
Lipodystrophy was clinically identified using qualitative physical examina- 
tion, and was defined subjectively as the presence of peripheral (face, arms, but- 
tocks, or legs) lipoatrophy and central (abdomen, dorsocervical spine region) 
fat accumulation. The presence of only signs of lipoatrophy (eg, peripheral fat 
loss, especially in the face or limbs) or fat accumulation was not classified as 
lipodystrophy. Lipodystrophy was assessed independent of the principal AE. 
Statistical Analysis 
Standard escriptive statistical analyses were performed to show the preva- 
lence of AEs. Statistical analyses were performed using SPSS version 11.50 
(SPSS Inc., Chicago, Illinois). 
RESULTS 
A total of 1391 patients (966 men, 425 women; mean age, 42 years [range, 18- 
67 years]) were enrolled. Demographic and clinical characteristics and anti- 
retroviral treatment history of the study population are shown in Table I. 
The mean duration of previous antiretroviral therapy was 74 months (range, 
6-156 months). Seven hundred nine patients (51.0%) were receiving fourth-line 
(or more) therapy. Eight hundred twenty-one patients (59.0%) were receiving 
treatment with an NNRTI, and 552 (59.0%) a PI, as a component of their HAART 
regimen at the time of occurrence of NRTI-related toxicities (Table I). The NRTIs 
with the highest discontinuation rates were stavudine (914 patients [65.7%]) and 
zidovudine (177 [12.7% ]). The most frequent NRTI-related AEs were lipoatrophy 
(550 patients [39.5%]) and peripheral neuropathy (170 [12.2%]). 
NRTl-associated toxicities leading to discontinuation (principal AEs) are 
shown in Table II. Overall, l ipodystrophy led to discontinuation i 142 patients 
(10.2%), and fat accumulation alone led to discontinuation i 28 (2.0%). The 
most common laboratory abnormality, anemia, was the principal AE in 77 pa- 
tients (5.5%). The figure shows the percentages of NRTIs associated with each 
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Table I. Demographic and clinical characteristics and antiretroviral treat- 
ment history of the study patients (N = 1391). 
Characteristic Value 
Age, mean (range), y 42 (18-67) 
Sex, no. (%) of patients 
Male 966 (69.4) 
Female 425 (30.6) 
Race, no. (%) of patients 
White 1 391 (100.0) 
Mode of infection, no. (%) of patients 
Intravenous drug use 680 (48.9) 
Heterosexual contact 359 (25.8) 
Homosexual contact 291 (20.9) 
Data not available 39 (2.8) 
Other* 22 (1.6) 
Degree of disease, no. (%) of patients 
AIDS t 506 (36.4) 
HIV-1 RNA <200 copies 1000 (71.9) 
CD 4 count, mean, cells x t06/L 527 
Previous antiretroviral therapy 
Agents received, mean 3 
Duration, mean (range), mo 74 (6-156) 
HAART components 
NRTIs 
Stavudine 
No. (%) of patients 1030 (74.0) 
Treatment duration, mean, mo 50.9 
Zidovudine 
No. (%) of patients 262 (18.8) 
Treatment duration, mean, mo 38.4 
Lamivudine 
No. (%) of patients 808 (58.1) 
Treatment duration, mean, mo 50.0 
Didanosine 
No. (%) of patients 545 (39.2) 
Treatment duration, mean, mo 39.0 
Abacavir 
No. (%) of patients 262 (18.8) 
Treatment duration, mean, mo 29.0 
PIs 
No. (%) of patients 552 (39.7) 
Treatment duration, mean, mo 34.4 
NNRTIs 
No. (%) of patients 821 (59.0) 
Treatment duration, mean, mo 38.7 
HAART = highly active antiretroviral therapy; NRTIs = nucleoside analogue reverse tran- 
scriptase inhibitors; PIs = protease inhibitors; NNRTIs = nonnucleoside reverse transcrip- 
tase inhibitors. 
*Includes blood transfusion, accidental, and unclear mode of infection. 
tCenters for Disease Control and Prevention Category C disease, is 
121 
CURRENT THERAPEUTIC RESEARCH 
Table II. Toxicities causing discontinuation of nucleoside analogue reverse 
transcriptase inhibitors in the study population (N --- 1391). 
Adverse Effect No. (%) of Patients 
Clinical abnormality 
Lipoatrophy 550 (39.5) 
Peripheral neuropathy 1 70 (12.2) 
Lipodystrophy* 142 (10.2) 
Vomiting 34 (2.4) 
Hypersensitivity reaction 29 (2.1) 
Fat accumulation 28 (2.0) 
Nausea 21 (1.5) 
Lactic acidosis 19 (1.4) 
Muscular pain 18 (1.3) 
Diarrhea 18 (1.3) 
Asthenia 15 (1.1) 
Cutaneous rash 11 (0.8) 
Pancreatitis 9 (0.6) 
Headache 6 (0.3) 
Fever 4 (0.3) 
Other t 32 (2.3) 
Laboratory abnormality 
Anemia (Fe <9.5 g/dL) 77 (5.5) 
Hypertriglyceridemia (TG >250 mg/dL) 37 (2.7) 
Elevated ALT (>2.5 x ULN) 18 (1.3) 
Hyperlactatemia (lactate >2 mmol/L) 
(asymptomatic) 16 (1.2) 
Leukopenia (WBC count <4000 cells/ML) 14 (1.0) 
Hyperamylasemia (amylase >1.39 x ULN) 13 (0.9) 
Elevated AST (>2.5 x ULN) 11 (0.8) 
Hypercholesterolemia (TC >220 mg/dL) 10 (0.7) 
Elevated CPK (>3 x ULN) 6 (0.4) 
Hyperglycemia (FPG >116 mg/dL) 3 (0.2) 
Thrombocytopenia 
(thrombocyte count, <75,000 cells/IJL) 1 (0.1) 
Other~ 12 (0.9) 
Fe = iron; TG = triglycerides; ALT = alanine aminotransferase; ULN = upper limit of normal; 
WBC = white blood cell; AST -- aspartate aminotransferase; TC = total cholesterol; 
CPK = creatine phosphokinase; FPG = fasting plasma glucose. 
*Lipodystrophy: 142 patients (10.2%) had lipoatrophy plus fat ccumulation. 
tlncludes end-stage hepatic disease, abdominal pain, gynecomastia, edemas, dyspepsia, 
arrhythmia, chemotherapy, and cholelithiases. 
~lncludes elevated lipase, macrocytosis, and T-glutamyltransferase increase. 
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Figure. Rates at which nucleoside analogue reverse transcriptase inhibitors were associ- 
ated with adverse effects in the study population (N -- 1391). *Lipodystrophy: 
142 patients (10.2%) had lipoatrophy plus fat accumulation. 
toxicity. The most common NRTI associated with ]ipoatrophy was stavudine 
(480/550 cases [87.3%]). Stavudine and didanosine were most commonly asso- 
ciated with peripheral neuropathy (107/170 [62.9%] and 48/170 [28.2%] cases, 
respectively). Zidovudine was most commonly associated with anemia (70/77 
cases [90.9%]). 
DISCUSSION 
This large-cohort analysis hows the impact of NRTI-related toxicities associat- 
ed with long-term HIV-1 management using NRTI-containing HAART regimens. 
Lipoatrophy was the most frequent principal AE and was most commonly asso- 
ciated with the use of stavudine. 16
Thymidine analogues have been associated with the development of lipoat- 
rophy. 9,1° Studies of switching from stavudine or zidovudine to abacavir due to this 
AE have shown little or no apparent improvement in peripheral fat wasting. 14,17 
However, it should be kept in mind that there is no widely accepted efinition 
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of HAART-associated lipoatrophy, and that little is known about the natural 
course of the lipodystrophy syndrome, defined as _>1 of the following clinical 
features 18: 
• No steroid therapy and no AIDS-related or other severe illness in the past 
3 months, and ___1 of the following: 
• Peripheral fat wasting; 
• Central adiposity and ___1 of the following: 
- Fasting triglyceride l vel >2.0 mmol/L; 
- Fasting total cholesterol level >5.5 mmol/L; 
- Fasting C-peptide level >2.5 nmol/L; 
- Impaired glucose tolerance. 
Other AEs, such as peripheral neuropathy, also frequently led to the discon- 
tinuation of an NRTI, in particular stavudine and didanosine) 3,19 With regard to 
laboratory abnormalities, anemia in association with zidovudine was the most 
frequently observed AE. On the other hand, dyslipidemia (historically associat- 
ed with the use of PIs) 3,20 was present in a considerable percentage of patients. 
Switching treatment in patients with clinically significant body-composition 
and/or metabolic hanges has been extensively investigated 14,21 in patients 
receiving PIs. The clinical benefits of switching one component of the NRTI 
regimen has been investigated more recently. In one study, 17,22 significant 
improvements in subcutaneous fat continued over 104 weeks after patients 
with moderate to severe lipodystrophy were switched from stavudine or 
zidovudine to abacavir. Another study explored switching from stavudine or 
zidovudine to tenofovir or abacavir to prevent he mitochondrial toxicity that 
causes many AEs associated with long-term HAART regimens consisting of ___1 
NRTI. In this study, switching from a thymidine analogue to abacavir or teno- 
fovir for 48 weeks led to similar, significant increases in limb fat. Although both 
agents maintain virologic suppression, tenofovir was associated with fewer 
treatment discontinuations and greater improvements in lipid parameters com- 
pared with abacavir. 23 
Stavudine-associated mitochondrial toxicity may play a role in the etiology 
of lipoatrophy. Two recent Spanish studies 24,25 explored the hypothesis that 
switching from stavudine to tenofovir would result in an increase in mitochon- 
drial DNA in peripheral blood mononuclear cells (PBMCs) and an improvement 
in lipid profile and peripheral lipoatrophy. In the Lipotest Study, 24 53 patients 
with HIV-1 RNA <50 copies/mL and lipoatrophy receiving stavudine (40 mg)-based 
antiretroviral therapy regimens were enrolled. Switching from stavudine to 
tenofovir was well tolerated, and virologic and immunologic success was main- 
tained. Patients howed a rapid improvement in lipid profile, decreased lactate 
levels, and a slight amelioration ofmitochondrial DNA content in PBMCs. In addi- 
tion, they presented a slow but significant recovery of the fat mass and the malar 
fat thickness. In the d4T40/30 Study, 25 56 patients with HIV-1 RNA <50 copies/mL 
and lipoatrophy receiving stavudine (40 mg)-based antiretroviral therapy regi- 
124 
R. Palacios et al. 
mens were enrolled. Patients were switched to stavudine 30 mg or tenofovir 
(both, n = 18) or continued with stavudine 40 mg (n = 20). Reducing the stavudine 
dose from 40 to 30 mg BID was as effective as switching from stavudine to teno- 
fovir. Both strategies were associated with decreased serum lipid levels and 
increased body fat, although the effect of switching to tenofovir was higher than 
that of reducing stavudine dose. 
Long-term follow-up of patients in the Recover Study cohort will provide 
important data concerning the management and outcomes of NRTI-associated 
toxicities. In a preliminary analysis of this cohort, switching from stavudine 
to tenofovir in virologically suppressed HIV-l-infected patients significantly 
improved hypercholesterolemia and hypertriglyceridemia in the short term 
(12 weeks) (P < 0.00I) .  26 
CONCLUSIONS 
The results of this study in patients with HIV-1 recruited from the Recover 
Study and receiving HAART suggest hat long-term treatment with NRTIs is 
associated with AEs 0ipoatrophy, peripheral neuropathy, and lipodystrophy), 
with morphologic disorders (lipoatrophy, lipodystrophy) being the most com- 
mon AEs leading to discontinuation. Minimizing these AEs by switching to 
another NRTI not associated with these AEs (eg, tenofovir) would contribute to 
adherence and hence efficacy of long-term HAART. 
ACKNOWLEDGMENTS 
The Recover Study is supported by a grant from Gilead Sciences, SL, Madrid, Spain. 
We thank Marta Pulido, MD, for her editorial assistance. 
REFERENCES 
1. Dieterich DT. Long-term complications of nucleoside reverse transcriptase inhibitor 
therapy. AIDS Read. 2003; 13:176-184, 187. 
2. Palella FJ Jr, Delaney KM, Moorman AC, et al, for the H1V Outpatient Study In- 
vestigators. Declining morbidity and mortality among patients with advanced 
human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860. 
3. Carr A, Cooper DA. Adverse ffects of antiretroviral therapy. Lancet. 2000;356:1423-1430. 
4. Cart A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyper- 
lipidaemia nd insulin resistance inpatients receiving HIV protease inhibitors. AIDS. 
1998;12:F51-F58. 
5. Safrin S, Grunfeld C. Fat distribution and metabolic hanges in patients with HIV 
infection. AIDS. 1999;13:2493-2505. 
6. Ammassari A, Antinori A, Cozzi-Lepri A, et al, for the AdICoNA Study Group and the 
LipoICoNA Study Group. Relationship between HAART adherence and adipose tissue 
alterations. J Acquir lnm une Defic Syndr. 2002 ;31 (Suppl 3):S 140-S 144. 
125 
CURRENT THERAPEUTIC RESEARCH 
7. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS. 1998; 12:F37-F39. 
8. Cart A, Samaras K, Chisholm D J, Cooper DA. Pathogenesis of HIV-l-protease 
inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, nd insulin resis- 
tance. Lancet. 1998;351:1881-1883. 
9. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting 
(lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 
1999;13:1659-1667. 
10. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse tran- 
scriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 
2000;14:1309-1316. 
11. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by 
nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogen- 
esis of antiretroviral-therapy-related ipo ystrophy. Lancet. 1999;354:1112-1115. 
12. Brinkman K. Editorial response: Hyperlactatemia and hepatic steatosis as features of 
mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin 
Infect Dis. 2000;31:167-169. 
13. Walker IdA, Setzer B, Venhoff N. Increased long-term itochondrial toxicity in combina- 
tions of nucleoside analogue reverse-transcriptase inhibitors. AIDS. 2002; 16:2165-2173. 
14. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: A review. Clin 
Infect Dis. 2002;35:1219-1230. 
15. Castro KG, Ward JW, Slutsker L, et al, for the Centers for Disease Control and Pre- 
vention, National Center for Infectious Diseases Division of HIV/AIDS. 1993 Revised 
classification system for HIV infection and expanded surveillance case definition for 
AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep. 1992; 18:RR-17. 
16. Gerschenson M. Mitochondria nd lipodystrophy: Where are we now? Antivir Ther. 
2003;8:261-263. 
17. Carr A, Workman C, Smith DE, et al, for the Mitochondrial Toxicity (MITOX) Study 
Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: 
A randomized trial. JAMA. 2002;288:207-215. 
18. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of 
HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, nd diabetes 
mellitus: A cohort study. Lancet. 1999;353:2093-2099. 
19. Lewis W. Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor 
therapy: Experimental c arifications and persistent clinical questions. Antiviral Res. 
2003;58:189-197. 
20. Moyle G, Carr A. HIV-associated lipodystrophy, metabolic omplications, and anti- 
retroviral toxicities. HIV Clin Trials. 2002;3:89-98. 
21. Martinez E, Arnaiz JA, Podzamczer D, et al, for the Nevirapine, Efavirenz, and 
Abacavir (NEFA) Study Team. Substitution of nevirapine, efavirenz, or abacavir for 
protease inhibitors in patients with human immunodeficiency virus infection. N Engl 
J Med. 2003;349:1036-1046. 
22. Martin A, Smith DE, Carr A, et al, for the Mitochondrial Toxicity Study Group. 
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from 
a thymidine analogue to abacavir: The MITOX Extension Study. AIDS. 2004;18: 
1029-1036. 
23. Moyle G, Sabin C, Cartledge J, et al. A 48-week, randomized, open-label comparative 
study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons 
126 
R. Palacios et al. 
with lipoatrophy and sustained virological suppression on HAART. Presented at: 
12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 
2005; Boston, Mass. Late Breaker 44. 
24. Ribera E, Paradineiro J, Sauleda S, et al. Improvement of subcutaneous fat, lipid pro- 
file and parameters ofmitochondrial toxicity in patients with peripheral lipoatrophy 
when stavudine is switched to tenofovir: The Lipotest Study. Poster presented at: 
12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; 
Boston, Mass. Poster 860. 
25. Milinkovic A, Lopez S, Vidal S, et al. A randomized open study comparing the impact 
of reducing stavudine dose vs switching to tenofovir on mitochondrial function, 
metabolic parameters, and subcutaneous fat in HIV-infected patients receiving anti- 
retroviral therapy containing stavudine. Poster presented at: 12th Conference on 
Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Mass. 
Poster 857. 
26. Domingo P, Labarga P, Palacios R, et al, for the Recover Study Group. Improvement 
of dyslipidemia in patients witching from stavudine to tenofovir: Preliminary re- 
sults. AIDS. 2004;18:1475-1478. 
Address correspondence to: Santiago Moreno Guillen, MD, PhD, Department 
of Infectious Diseases, Hospital RamOn y Cajal, Carretera de Colmenar Viejo 
Km 9.1, Madrid 28034, Spain. E-mail: smoreno.hrc@salud.madrid.org 
127 
CURRENT THERAPEUTIC RESEARCH 
Appendix. The Recover Study Group. 
Members of the Recover Study Group include: P. S~iz de la Hoya, MD, Centro Penitenciario 
de Alicante, Alicante; A. Mari~o, MD, Complexo Hospitalario Arquitecto Marcide, El Ferrol; 
R. Ojea, MD, Complexo Hospitalario de Pontevedra, Pontevedra; M. Aranda, MD, Consorsi 
Sanitari de Terrasa, Barcelona; M. Fernandez, MD, Fundaci6n Jim~nez Dias, Madrid; 
M.L. Alvarez, MD, P. Ferrer, L. Herrera, MD, P. Mallaina, MD, PhD, S. P~rez, and R. S~nchez 
de la Rosa, MD, PhD, Gilead Sciences, Madrid; R. Herv~s, MD, Hospital 12 de Octubre, 
Madrid; C. Galera, MD, Hospital de la Arrixaca, Murcia; R. Teira, MD, Hospital de Basurto, 
Bilbao; B. De la Fuente, MD, Hospital de Cabue~es, Gij6n; R. Canet, MD, Hospital Can 
Misses, Islas Baleares; J.M. Ant6nez, MD, Hospital Carlos Haya, M~laga; L. Porras, MD, 
Hospital de Ciudad Real, Ciudad Real; V. Estrada, MD, and M.J. T~llez, MD, Hospital Clinico 
San Carlos, Madrid; J. Hern~ndez Quero, MD, Hospital Clinico San Cecilio, Granada; 
E. Losada, MD, and A. Prieto, MD, Hospital Clfnico de Santiago de Compostela, Santiago de 
Compostela; M.J. Galindo, MD, Hospital Clinico Universitario de Valencia, Valencia; L. Ferrer, 
MD, Hospital de la Creu Roje de Barcelona, Barcelona; C. Cortes, MD, and I. Garcia, MD, 
Hospital de la Creu Roje de Hospitalet, Barcelona; J.M. Zarzalejos, MD, Hospital Doctor 
Negr~n, Islas Canarias; J. Carmena, MD, and R. Vicente, MD, Hospital Doctor Peset, 
Valencia; X. Camino, MD, Hospital de Donosti, San Sebastian; J. Colomina, MD, Hospital 
de EIda, Alicante; M. Salavert, MD, Hospital de la Fe, Valencia; S. Vega, MD, Hospital de 
Figueres, Girona; C. Mingues, MD, Hospital General de Castell6n, Castell6n; A. Cano, MD, 
Hospital General de Murcia, Murcia; J. S~nchez Navarro, MD, Hospital General R~o Carri6n, 
Palencia; E. Ortega, MD, Hospital General de Valencia, Valencia; ]. Vilar6, MD, Hospital 
General de Vic, Vic; G. Esquinas, MD, Hospital de Getafe, Madrid; E. Pedrol, MD, Hospital 
de Granollers, Granollers; J. Berenguer, MD, J. Cosin, MD, P. Miralles, MD, and B. Padilla, 
Hospital Gregorio Mara~6n, Madrid; M. Rodriguez, MD, Hospital de Guadalajara, 
Guadalajara; F. B~guena, MD, Hospital de Igualada, Barcelona; F. Garcia, MD, and 
A. Mu~oz, MD, Hospital Infanta Cristina, Badajoz; A. Menchero, MD, Hospital Infanta Elena, 
Huelva; ].A. Terr6n, MD, Hospital de Jerez, Jerez; J. Pedreira, MD; Hospital Juan Canalejo, 
Coru~a; R. Creagh, MD, Hospital Juan Ram6n Jim~nez, Huelva; J. Mascar6, MD, Hospital 
Josep Trueta, Barcelona; J. L6pez Aldeguer, Hospital La Fe, Valencia; J.R. Barber~, MD, 
Hospital La Mancha Centro, Alcazar de San Juan; S. Hern~ndez, MD, and A. Lorenzo, MD, 
Hospital La Paz, Madrid; I. Sanz Moreno, MD, Hospital La Princesa, Madrid; D. Pe~a, MD, 
Hospital de la Linea, Algeciras; H. Knobel, MD, PhD, Hospital del Mar, Barcelona; 
F. Pasquau, MD, Hospital Marina Baixa, Alicante; S. Echevarria, MD, and C. Fari~as, MD, 
Hospital Marquis de Valdecilla, Santander; P. Barrufet, MD, and L. Force, MD, Hospital de 
Matar6, Matar6; A. Asorey, MD, Hospital Do Meixoeiro, Vigo; P. Arazo, MD, Hospital 
Miguel Servet, Zaragoza; C. Barros, MD, Hospital de M6stoles, Madrid; V. Guti~rrez-Rave, 
MD, Hospital de Motril, Almeria; F. Marcos, MD, Hospital Nuestra Se~ora del Prado, Ciudad 
Real; M. Cervantes, MD, Hospital Parc Tauli, Sabadell; M. Delgado, MD, Hospital de 
Poniente, AImerla; T. Martin, MD, Hospital Puerta de Hierro, Madrid; I. Vigueras, MD, 
Hospital Rafael M~ndez, Murcia; A. Antela, MD, ].L. Casado, MD, F. Dronda, MD, 
S. Moreno Guillen, MD, PhD, and M.J. P~rez Elias, MD, PhD, Hospital Ram6n y Cajal, 
Madrid; M. Cordero, MD, Hospital de Salamanca, Salamanca; J. Blanch, MD, and L. Moner, MD, 
Hospital de San Camil, St. Pere de Ribes; R. Silvari~o, MD, Hospital de San Eloy, Barakaldo; 
M. Egido, MD, Hospital de San ]orge, Huesca; J.M. Cuadrado, MD, Hospital de San Juan, 
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Alicante; P. Labarga, MD, Hospital de San Mill~n, Logro~o; ].M. Llibre, MD, Hospital Sant 
Llaume, Calella; P. Domingo, MD, PhD, Hospital Sant Pau, Barcelona; A. Delegido, MD, 
Hospital de Sant Pau i Santa Tecla, Tarragona; R. Rodriguez, MD, Hospital Santa Maria 
Nai, Pontevedra; J.A. Garc~a, MD, Hospital Santa Maria Rosell, Cartagena; ]. Elizaga, MD, 
Hospital de Segovia, Segovia; R. Torres Perea, MD, Hospital Severo Ochoa, Madrid; M. 
Leyes, MD, J. Murillas, MD, M. Riera, MD, PhD, and A. Salas, MD, Hospital de Son Dureta, 
Islas Baleares; M. Aldamiz, MD, Hospital de Txagorritxu, Vitoria; J.L. G6mez, MD, Hospital 
Universitario de Canarias, Islas Canarias; V. Falc6, MD, I. Oca~a, MD, C. Pigrau, MD, 
E. Ribera, MD, PhD, and M.I. Ruiz, MD, Hospital de Vail d'Hebr6n, Barcelona; A. Orti, MD, 
Hospital Verge de la Cinta, Tarragona; C. Rosa Herranz, MD, Hospital Virgen de la Luz, 
Cuenca; M.A. Munia~n, MD, and L. Orbea, MD, Hospital Virgen de la Macarena, Sevilla; 
F. Cuadra, MD, Hospital Virgen de la Salud, Toledo; R. Palacios, MD, PhD, and J. Santos, MD, 
Hospital Virgen de la Victoria, M~laga; C. Miralles, MD, and A. Ocampo, MD, Hospital Xeral 
Cies, Vigo; and A. Chocarro, MD, Hospital de Zamora, Zamora. 
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